Our methodology is published, not asserted.
Most imaging providers describe their methods in their own materials. Ours have been through peer review — the platform, the standardisation programme and the quantitative methods behind it. Whether you are designing a study or assessing an imaging provider, the method is on the record and you can read it.
The papers below are of two kinds: those that describe the methods, broken out below by what each one establishes, and those reporting trial results where central imaging review ran on WIDEN.
Grouped by what each paper establishes.
Newest first within each group. Where a trial is already public under its own name, it is marked.
Central review in multicentre trials
- Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi (opens in a new tab)
- End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial (opens in a new tab)
- Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe) (opens in a new tab)
- Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study (opens in a new tab)
- Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe) (opens in a new tab)
Standardisation and site qualification
Quantitative imaging
- Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial (opens in a new tab)
- Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study (opens in a new tab)
- Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 Trial (opens in a new tab)
- Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial (opens in a new tab)
- PET-Based Risk Stratification in Primary Mediastinal B-Cell Lymphoma: A Comparative Analysis of Different Segmentation Methods in the IELSG37 Trial Patient Cohort (opens in a new tab)
- PSMA and FDG-PET as predictive and prognostic biomarkers in patients given 177Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial (opens in a new tab)
- Automatic liver detection and standardised uptake value evaluation in whole-body Positron Emission Tomography/Computed Tomography scans (opens in a new tab)
Trial results
- Overall survival and quality of life with 177Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial (opens in a new tab)
- Overall survival with 177Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial (opens in a new tab)
- 177Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial (opens in a new tab)
- Sequential 177Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study (opens in a new tab)
- Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results (opens in a new tab)
- 177Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial (opens in a new tab)
- ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901) (opens in a new tab)
- UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol) (opens in a new tab)
- TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603) (opens in a new tab)
The platform itself
Dixit scientists also appear on further papers reporting results from trials whose imaging ran on WIDEN. This list covers those we can cite directly.
Every entry links through its DOI rather than a publisher URL, so the reference cannot rot. Publication metadata is verified against Crossref, and trial registrations against ClinicalTrials.gov. Years are journal issue years, not online-first dates.
Ask us how the method applies to your trial.
The scientists who wrote these papers are the ones who design the endpoints, qualify the sites and govern the review on your study — sponsor-run or investigator-initiated.